ArticleFrontiers in psychiatry2025
Effects of paroxetine combined with sulpiride on sleep status and quality of life in patients with depressive episodes.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Assess the clinical efficacy of paroxetine and sulpiride IV drip in treating depression and its impact on sleep and quality of life. Methods: Retrospective analysis of 80 depression patients, divided into a study group treated with paroxetine and sulpiride IV drip, and a control group treated with paroxetine alone, over 8 weeks. HAMD and SF-36 assessed depression and quality of life; TESS evaluated adverse reactions. Results: HAMD scores decreased in both groups, with the study group showing better depression status at 1, 2, and 4 weeks (P<0.05) and higher effective rates (P<0.05). The study group had faster symptom relief. SF-36 scores in role physical, general health, vitality, and role emotional were higher in the study group (P<0.05). TESS scores showed no significant difference between groups (P>0.05), with mild adverse reactions. Conclusion: Paroxetine with sulpiride IV drip offers rapid relief and high safety in depression treatment, improving sleep and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.